Published Date: 17 Feb 2023
For people previously infected with COVID-19, analysis and assessment showed an 88% lower rate of hospitalization or death for at least 10 months compared to people who had no pre-existing disease .
Read Full NewsSpotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD
Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial
FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis
FDA News Recap: Novel Drug Approvals in Q2 2026
Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.
August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.
Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.
1.
Poor agreement between diagnostic tests for breast cancer-related lymphedema
2.
Massachusetts nurses with brain tumors: Department of Public Health 'in communication' with Newton-Wellesley
3.
GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer
4.
Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.
5.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
1.
Cancer Across the Lifespan: Precision Strategies for Pediatric and Geriatric Oncology
2.
Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives
3.
Emerging and Innovative Therapies in Cancer Treatment and Post-Surgical Care
4.
Spatial Tumor Mapping for Individualized Cancer Therapy
5.
Quality of Life Using Precision Functional Recovery After Organ-Preserving Interventions
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Understanding the causes of anemia in adults beyond nutritional deficiencies
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
5.
Innovations in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation